Download File - JOHN J. HADDAD, Ph.D.

More documents

Recommendations

Info

Development of Novel Immunotherapeutics 179 5. Denkberg G, Cohen CJ, Lev A, et al. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci USA 2002; 99(14):9421–9426. 6. Liu MA. The immunologist’s grail: vaccines that generate cellular immunity. Proc Natl Acad Sci USA 1997; 94(20):10496–10498. 7. Glenting J, Wessels S. Ensuring safety of DNA vaccines. Microb Cell Fact 2005; 4:26. 8. Coelho-Castelo AAM, Trombone AP, Rosada RS, et al. Tissue distribution of a plasmid DNA encoding Hsp65 gene is dependent on the dose administered through intramuscular delivery. Genet Vaccines Ther 2006; 4:1. 9. Bot A, Stan A.-S., Inaba K., et al. Dendritic cells at a DNA vaccination site express an encoded influenza nucleoprotein and prime CD8þ cytolytic lymphocytes upon adoptive transfer. Int Immunol 2000; 12:825–832. 10. Maloy KJ, Erdmann I, Basch V, et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001; 98(6):3299–3303. 11. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993; 90(24):11478–11482. 12. Tagawa ST, Lee P, Snively J, et al. <strong>Ph</strong>ase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 2003; 98(1):144–154. 13. Weber J, Boswell W, Smith J, et al. <strong>Ph</strong>ase I trial of intranodal injection of a Melan-A/ MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2007 (in press). 14. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8þ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99:16168–16173. 15. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109(3):409–417. 16. von Beust BR, Johansen P, Smith KA, et al. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol 2005; 35:1869–1876. 17. Smith KA, Qiu Z, Der-Sarkissian A, et al. Immunological Control and Regression of Solid Tumors Achieved by Lymph Node Targeted Immunotherapy. Los Angeles, CA: International Society for Biological Therapy of Cancer, 2006 (J Immunother 2006; 29(6):676–677). 18. Bot A, Qiu Z, Liu L, et al. A novel class of biotherapeutics co-targeting cancer cells and the associated tumor neovasculature. Alexandria, VA: International Society for Biological Therapy of Cancer, 2005 (J Immunother 2005; 28(6):637–638). 19. Smith K, Qiu Z, Tam V, et al. DNA Vaccination Revisited: Induction of Potent Immunity by Sequential Injection of Lymph Nodes with Plasmid Vectors and Peptides. Los Angeles: Annual AACR Meeting, 2007. 20. Busch DH, Pamer EG. MHC class I/peptide stability: implications for immunodominance, in vitro proliferation, and diversity of responding CTL. J Immunol 1998; 160(9):4441–4448.
180 Bot and Obrocea 21. Hoos A, Parmiani G, Hege K, et al. Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 1997–2007; 30(1):1–15. 22. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259(5102):1745–1749. 23. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3(8):849–854. 24. Mashino K, Sadanaga N, Tanaka F, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001; 85(5): 713–720.
Page 1 and 2:
Translational Medicine Series 6 Can
Page 3 and 4:
TRANSLATIONAL MEDICINE SERIES 1. Pr
Page 5 and 6:
Informa Healthcare USA, Inc. 52 Van
Page 8 and 9:
Preface Throughout the last 20 year
Page 10 and 11:
Preface vii Table 1 A Diverse Techn
Page 12 and 13:
Preface . . . . v Contributors . .
Page 14 and 15:
Contributors Pedro Alves Ludwig Ins
Page 16 and 17:
1 Factoring in Antigen Processing i
Page 18 and 19:
Factoring in Antigen Processing in
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
2 Outlining the Gap Between Preclin
Page 48 and 49:
Preclinical Models and Clinical Sit
Page 50 and 51:
Table 1 Examples of Preclinical Act
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68:
Page 71 and 72:
56 Srinivasan disease agents. Garda
Page 73 and 74:
58 Srinivasan expressing various kn
Page 75 and 76:
60 Srinivasan The above-mentioned a
Page 77 and 78:
62 Srinivasan (69). In another stud
Page 79 and 80:
64 Srinivasan patients with prostat
Page 81 and 82:
66 Srinivasan 33. Salgia R, Lynch T
Page 83 and 84:
68 Srinivasan 67. Werness BA, Levin
Page 85 and 86:
70 Teofilovici and Wentworth In 190
Page 87 and 88:
72 Teofilovici and Wentworth conduc
Page 89 and 90:
74 Teofilovici and Wentworth Lipono
Page 91 and 92:
76 Teofilovici and Wentworth (best
Page 93 and 94:
78 Teofilovici and Wentworth nature
Page 95 and 96:
80 Teofilovici and Wentworth In the
Page 97 and 98:
82 Teofilovici and Wentworth 17. Ba
Page 99 and 100:
84 Luptrawan et al. Dendritic cells
Page 101 and 102:
86 Luptrawan et al. of cancer cells
Page 103 and 104:
88 Luptrawan et al. NK cells can ki
Page 105 and 106:
90 Luptrawan et al. Figure 2 Repres
Page 107 and 108:
92 Luptrawan et al. state (50). Pat
Page 109 and 110:
94 Luptrawan et al. ability of TIL
Page 111 and 112:
96 Luptrawan et al. Figure 4 Drug s
Page 113 and 114:
98 Luptrawan et al. Figure 6 Tumor
Page 115 and 116:
Table 1 Summary of results of phase
Page 117 and 118:
102 Luptrawan et al. Table 1 Summar
Page 119 and 120:
104 Luptrawan et al. antigens (84,8
Page 121 and 122:
106 Luptrawan et al. 30. Ranges GE,
Page 123 and 124:
108 Luptrawan et al. 66. Dunn GP, B
Page 125 and 126:
110 Schroter and Minev proteins (2,
Page 127 and 128:
112 Schroter and Minev tumor-challe
Page 129 and 130:
114 Schroter and Minev Table 1 Inve
Page 131 and 132:
116 Schroter and Minev Table 1 Inve
Page 133 and 134:
118 Schroter and Minev demonstrated
Page 135 and 136:
120 Schroter and Minev loaded MART-
Page 137 and 138:
122 Schroter and Minev illustrate t
Page 139 and 140:
124 Schroter and Minev 4. Heemels M
Page 141 and 142:
126 Schroter and Minev 42. Minev BR
Page 143 and 144:
128 Schroter and Minev 74. Restifo
Page 146 and 147:
7 Multimodality Immunization Approa
Page 148 and 149: Multimodality Immunization Approach
Page 162 and 163: Figure 5.1 Immunohistochemical char
Page 164 and 165: Figure 8.5 A schematic representati
Page 170 and 171: 8 Bidirectional Bedside Lab Bench P
Page 172 and 173: Development of Novel Immunotherapeu
Page 200 and 201: 9 Diagnostic Approaches for Selecti
Page 202 and 203: Diagnostic Approaches to Maximize T
Page 222: Diagnostic Approaches to Maximize T
Page 225 and 226: 206 Index Antigenic peptides degrad
Page 227 and 228: 208 Index Chromogens, enzymatic act
Page 229 and 230: 210 Index Freund’s adjuvants. See
Page 231 and 232: 212 Index Langerhans cells, 133, 13
Page 233 and 234: 214 Index [Peptide vaccines] invest
Page 235 and 236: 216 Index TCRL. See TCR-like immuno
Page 238: Oncology and Immunology about the b
show all

Download File - JOHN J. HADDAD, Ph.D.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?